CHDM clinical trials at University of California Health

1 research study open to eligible people

Showing trials for

  • DMCRN-02-001: Assessing Pediatric Endpoints in DM1

    open to eligible people ages up to 59 months

    The overall goal of the study is to establish valid clinical endpoint assessments for children with congenital myotonic dystrophy type 1 and childhood myotonic dystrophy type 1, and develop biomarkers for the condition.

    at UCLA

Our lead scientists for CHDM research studies include .

Last updated: